eLiquid biopsy detects early lung cancerDecember 13, 2018
Wei et al demonstrate electric field-induced release and measurement (EFIRM) as a novel platform for liquid biopsy (LB) which enables the diagnosis of early-stage non-small-cell lung cancer (NSCLC) when surgical cure is still possible. The EFIRM-liquid biopsy (eLB) accurately detects two actionable epidermal growth factor receptor (EGFR) mutations seen in the blood of patients with early-stage NSCLC. The study showed specific detection of two specific EGFR mutations- p.L858R and Exon 19del. The scientists collected plasma samples from 248 patients with suspected lung cancer, of which 44 were diagnosed with Stage I or Stage II NSCLC. EFIRM was able to detect the p.L858R mutation in 11 of 12 samples and the Exon 19del mutation in seven of nine samples, resulting in greater than 90 percent sensitivity and 80 percent specificity. The clinical sensitivity of EFIRM to detect patients with early-stage NSCLC is limited by the percentage of tumours containing either or both of the two variants, which is estimated at 27 percent of NSCLC tumours. The research suggests more studies to be performed to optimize the technical and clinical performance of the assay which once validated can be useful in screening and for many other high-throughput applications.
The Journal of Molecular Diagnostics, November 2018, Volume 20, Issue 6, Pages 738–742 / https://doi.org/10.1016/j.jmoldx.2018.06.008/